Bain Capital Life Sciences Investors, LLC Buys SpringWorks Therapeutics Inc, Constellation Pharmaceuticals Inc, Savara Inc, Sells Dicerna Pharmaceuticals Inc

Feb 17, 2020

Investment company Bain Capital Life Sciences Investors, LLC (Current Portfolio) buys SpringWorks Therapeutics Inc, Constellation Pharmaceuticals Inc, Savara Inc, X4 Pharmaceuticals Inc, sells Dicerna Pharmaceuticals Inc during the 3-months ended 2019Q4, according to the most recent filings of the investment company, Bain Capital Life Sciences Investors, LLC. As of 2019Q4, Bain Capital Life Sciences Investors, LLC owns 10 stocks with a total value of $671 million. These are the details of the buys and sells.

New Purchases: SWTX, CNST, SVRA, XFOR,
Added Positions: MRNS,
Reduced Positions: DRNA,

For the details of Bain Capital Life Sciences Investors, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/bain+capital+life+sciences+investors%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Bain Capital Life Sciences Investors, LLC

SpringWorks Therapeutics Inc (SWTX) - 7,281,307 shares, 41.80% of the total portfolio. New Position
Constellation Pharmaceuticals Inc (CNST) - 2,823,529 shares, 19.84% of the total portfolio. New Position
Dicerna Pharmaceuticals Inc (DRNA) - 4,080,237 shares, 13.41% of the total portfolio. Shares reduced by 44.34%
Dynavax Technologies Corp (DVAX) - 8,452,235 shares, 7.21% of the total portfolio.
Replimune Group Inc (REPL) - 2,838,968 shares, 6.08% of the total portfolio.

New Purchase: SpringWorks Therapeutics Inc (SWTX)

Bain Capital Life Sciences Investors, LLC initiated holding in SpringWorks Therapeutics Inc. The purchase prices were between $17.74 and $39.52, with an estimated average price of $23.67. The stock is now traded at around $31.45. The impact to a portfolio due to this purchase was 41.8%. The holding were 7,281,307 shares as of .

New Purchase: Constellation Pharmaceuticals Inc (CNST)

Bain Capital Life Sciences Investors, LLC initiated holding in Constellation Pharmaceuticals Inc. The purchase prices were between $7.56 and $49.3, with an estimated average price of $29.67. The stock is now traded at around $36.06. The impact to a portfolio due to this purchase was 19.84%. The holding were 2,823,529 shares as of .

New Purchase: Savara Inc (SVRA)

Bain Capital Life Sciences Investors, LLC initiated holding in Savara Inc. The purchase prices were between $0.71 and $4.91, with an estimated average price of $1.19. The stock is now traded at around $2.45. The impact to a portfolio due to this purchase was 3.43%. The holding were 5,128,593 shares as of .

New Purchase: X4 Pharmaceuticals Inc (XFOR)

Bain Capital Life Sciences Investors, LLC initiated holding in X4 Pharmaceuticals Inc. The purchase prices were between $9.93 and $14.33, with an estimated average price of $11.92. The stock is now traded at around $9.20. The impact to a portfolio due to this purchase was 2.63%. The holding were 1,648,485 shares as of .

Here is the complete portfolio of Bain Capital Life Sciences Investors, LLC. Also check out:

1. Bain Capital Life Sciences Investors, LLC's Undervalued Stocks
2. Bain Capital Life Sciences Investors, LLC's Top Growth Companies, and
3. Bain Capital Life Sciences Investors, LLC's High Yield stocks
4. Stocks that Bain Capital Life Sciences Investors, LLC keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.